2024
US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization
Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Howard J. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes 2024, 11: 593-601. PMID: 39470958, PMCID: PMC11589080, DOI: 10.1007/s40801-024-00457-8.Peer-Reviewed Original ResearchHealthcare resource utilizationAssociated healthcare resource utilizationRescue therapy useEculizumab treatmentMyasthenia gravisMG exacerbationEculizumab initiationTherapy useMethodsA retrospective chart reviewTerminal complement inhibitor eculizumabRetrospective chart review analysisRates of healthcare resource utilizationComplement inhibitor eculizumabGeneralized myasthenia gravisRetrospective chart reviewChart review analysisTreatment of patientsUS adultsEculizumab therapyAcute clinical eventsMG crisisRescue therapyChart reviewEculizumabTherapy administrationUnited States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use
Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Nowak R, Howard J. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal Of Neurology 2024, 271: 6114-6126. PMID: 39052039, PMCID: PMC11377470, DOI: 10.1007/s00415-024-12569-w.Peer-Reviewed Original ResearchMinimal symptom expression’Minimal manifestation statusGeneralized myasthenia gravisEculizumab initiationEculizumab treatmentTotal scoreMG-ADLPrednisone dosageMyasthenia gravisMethodsA retrospective chart reviewComplement C5 inhibitor eculizumabSteroid-sparing effectAssociated with sustained improvementOpen-label extensionEffectiveness of eculizumabImmunosuppressive therapy useConcomitant medication useRetrospective chart reviewNonsteroidal immunosuppressive therapyMyasthenia Gravis-ActivitiesTreatment-refractoryC5 inhibitor eculizumabDiscontinue prednisoneImmunosuppressive therapySymptom expression
2022
Real-world experience of eculizumab treatment for generalized myasthenia gravis: initial data from a registry of patients with generalized myasthenia gravis in the USA (S25.006)
Narayanaswami P, Cutter G, Nowak R, Greene E, Muppidi S, Mozaffar T, Rodrigues E, Korideck H, Howard J. Real-world experience of eculizumab treatment for generalized myasthenia gravis: initial data from a registry of patients with generalized myasthenia gravis in the USA (S25.006). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1320.Peer-Reviewed Original Research
2019
A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates
Siddiqi Z, Howard J, Jacob S, Guptill J, Meisel A, Wiendl H, Murai H, Utsugisawa K, Nowak R, Fujita K, O’Brien F, Patra K, Muppidi S. A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s8-s8. DOI: 10.1017/cjn.2019.83.Peer-Reviewed Original ResearchPre-study yearOpen-label extensionHealthcare resource utilizationMyasthenia gravisEculizumab treatmentDisease burdenSignificant healthcare resource utilizationAnti-acetylcholine receptorExacerbations/hospitalizationsGreater disease burdenPoisson regression modelsMG crisisTherapy ratesRescue therapyResponsive patientsTherapy useTherapy usageClinical endpointsExacerbationHospitalizationPatientsMeaningful benefitREGAIN studyPatient recordsEvent rates